We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Read MoreHide Full Article
Analysts on Wall Street project that Thermo Fisher Scientific (TMO - Free Report) will announce quarterly earnings of $5.22 per share in its forthcoming report, representing a decline of 2.8% year over year. Revenues are projected to reach $10.65 billion, increasing 1% from the same quarter last year.
The current level reflects an upward revision of 0.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Thermo Fisher metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Revenues- Laboratory Products and Biopharma Services' at $5.74 billion. The estimate indicates a change of -0.2% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Specialty Diagnostics' will reach $1.14 billion. The estimate suggests a change of +2.5% year over year.
The combined assessment of analysts suggests that 'Revenues- Life Sciences Solutions' will likely reach $2.40 billion. The estimate suggests a change of +2.1% year over year.
The consensus among analysts is that 'Revenues- Analytical Instruments' will reach $1.79 billion. The estimate indicates a year-over-year change of +0.7%.
The collective assessment of analysts points to an estimated 'Geographic Revenues- Customer Location- North America' of $5.56 billion. The estimate indicates a change of +0.5% from the prior-year quarter.
The consensus estimate for 'Geographic Revenues- Customer Location- Asia-Pacific' stands at $1.98 billion. The estimate indicates a change of +0.4% from the prior-year quarter.
Analysts' assessment points toward 'Geographic Revenues- Customer Location- Other regions' reaching $391.38 million. The estimate points to a change of +3.3% from the year-ago quarter.
Analysts predict that the 'Geographic Revenues- Customer Location- Europe' will reach $2.69 billion. The estimate suggests a change of +0.9% year over year.
Over the past month, shares of Thermo Fisher have returned +8.3% versus the Zacks S&P 500 composite's +5.4% change. Currently, TMO carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Thermo Fisher (TMO) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Analysts on Wall Street project that Thermo Fisher Scientific (TMO - Free Report) will announce quarterly earnings of $5.22 per share in its forthcoming report, representing a decline of 2.8% year over year. Revenues are projected to reach $10.65 billion, increasing 1% from the same quarter last year.
The current level reflects an upward revision of 0.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Thermo Fisher metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Revenues- Laboratory Products and Biopharma Services' at $5.74 billion. The estimate indicates a change of -0.2% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Specialty Diagnostics' will reach $1.14 billion. The estimate suggests a change of +2.5% year over year.
The combined assessment of analysts suggests that 'Revenues- Life Sciences Solutions' will likely reach $2.40 billion. The estimate suggests a change of +2.1% year over year.
The consensus among analysts is that 'Revenues- Analytical Instruments' will reach $1.79 billion. The estimate indicates a year-over-year change of +0.7%.
The collective assessment of analysts points to an estimated 'Geographic Revenues- Customer Location- North America' of $5.56 billion. The estimate indicates a change of +0.5% from the prior-year quarter.
The consensus estimate for 'Geographic Revenues- Customer Location- Asia-Pacific' stands at $1.98 billion. The estimate indicates a change of +0.4% from the prior-year quarter.
Analysts' assessment points toward 'Geographic Revenues- Customer Location- Other regions' reaching $391.38 million. The estimate points to a change of +3.3% from the year-ago quarter.
Analysts predict that the 'Geographic Revenues- Customer Location- Europe' will reach $2.69 billion. The estimate suggests a change of +0.9% year over year.
View all Key Company Metrics for Thermo Fisher here>>>Over the past month, shares of Thermo Fisher have returned +8.3% versus the Zacks S&P 500 composite's +5.4% change. Currently, TMO carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .